Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre

Flash glucose monitoring (FGM) and real-time continuous glucose monitoring (RT-CGM) are increasingly used in clinical practice, with improvements in HbA1c and time in range (TIR) reported in clinical studies. We aimed to evaluate the impact of FGM and RT-CGM use on glycaemic outcomes in adults with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kyuhan Lee, Shakthi Gunasinghe, Alyson Chapman, Lynne A. Findlow, Jody Hyland, Sheetal Ohol, Andrea Urwin, Martin K. Rutter, Jonathan Schofield, Hood Thabit, Lalantha Leelarathna
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	type 1 diabetes flash glucose monitoring continuous glucose monitoring Freestyle Libre Dexcom G6 Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/2ef86de035a34cff94019bb89f5ec5ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2ef86de035a34cff94019bb89f5ec5ae
record_format	dspace
spelling	oai:doaj.org-article:2ef86de035a34cff94019bb89f5ec5ae2021-11-25T16:55:38ZReal-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre10.3390/bios111104572079-6374https://doaj.org/article/2ef86de035a34cff94019bb89f5ec5ae2021-11-01T00:00:00Zhttps://www.mdpi.com/2079-6374/11/11/457https://doaj.org/toc/2079-6374Flash glucose monitoring (FGM) and real-time continuous glucose monitoring (RT-CGM) are increasingly used in clinical practice, with improvements in HbA1c and time in range (TIR) reported in clinical studies. We aimed to evaluate the impact of FGM and RT-CGM use on glycaemic outcomes in adults with type 1 diabetes (T1DM) under routine clinical care. We performed a retrospective data analysis from electronic outpatient records and proprietary web-based glucose monitoring platforms. We measured HbA1c (pre-sensor vs. on-sensor data) and sensor-based outcomes from the previous three months as per the international consensus on RT-CGM reporting guidelines. Amongst the 789 adults with T1DM, HbA1c level decreased from 61.0 (54.0, 71.0) mmol/mol to 57 (49, 65.8) mmol/mol in 561 people using FGM, and from 60.0 (50.0, 70.0) mmol/mol to 58.8 (50.3, 66.8) mmol/mol in 198 using RT-CGM (<i>p</i> < 0.001 for both). We found that 23% of FGM users and 32% of RT-CGM users achieved a time-in-range (TIR) (3.9 to 10 mmol/L) of >70%. For time-below-range (TBR) < 4 mmol/L, 70% of RT-CGM users and 58% of FGM users met international recommendations of <4%. Our data add to the growing body of evidence supporting the use of FGM and RT-CGM in T1DM.Kyuhan LeeShakthi GunasingheAlyson ChapmanLynne A. FindlowJody HylandSheetal OholAndrea UrwinMartin K. RutterJonathan SchofieldHood ThabitLalantha LeelarathnaMDPI AGarticletype 1 diabetesflash glucose monitoringcontinuous glucose monitoringFreestyle LibreDexcom G6BiotechnologyTP248.13-248.65ENBiosensors, Vol 11, Iss 457, p 457 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	type 1 diabetes flash glucose monitoring continuous glucose monitoring Freestyle Libre Dexcom G6 Biotechnology TP248.13-248.65
spellingShingle	type 1 diabetes flash glucose monitoring continuous glucose monitoring Freestyle Libre Dexcom G6 Biotechnology TP248.13-248.65 Kyuhan Lee Shakthi Gunasinghe Alyson Chapman Lynne A. Findlow Jody Hyland Sheetal Ohol Andrea Urwin Martin K. Rutter Jonathan Schofield Hood Thabit Lalantha Leelarathna Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
description	Flash glucose monitoring (FGM) and real-time continuous glucose monitoring (RT-CGM) are increasingly used in clinical practice, with improvements in HbA1c and time in range (TIR) reported in clinical studies. We aimed to evaluate the impact of FGM and RT-CGM use on glycaemic outcomes in adults with type 1 diabetes (T1DM) under routine clinical care. We performed a retrospective data analysis from electronic outpatient records and proprietary web-based glucose monitoring platforms. We measured HbA1c (pre-sensor vs. on-sensor data) and sensor-based outcomes from the previous three months as per the international consensus on RT-CGM reporting guidelines. Amongst the 789 adults with T1DM, HbA1c level decreased from 61.0 (54.0, 71.0) mmol/mol to 57 (49, 65.8) mmol/mol in 561 people using FGM, and from 60.0 (50.0, 70.0) mmol/mol to 58.8 (50.3, 66.8) mmol/mol in 198 using RT-CGM (<i>p</i> < 0.001 for both). We found that 23% of FGM users and 32% of RT-CGM users achieved a time-in-range (TIR) (3.9 to 10 mmol/L) of >70%. For time-below-range (TBR) < 4 mmol/L, 70% of RT-CGM users and 58% of FGM users met international recommendations of <4%. Our data add to the growing body of evidence supporting the use of FGM and RT-CGM in T1DM.
format	article
author	Kyuhan Lee Shakthi Gunasinghe Alyson Chapman Lynne A. Findlow Jody Hyland Sheetal Ohol Andrea Urwin Martin K. Rutter Jonathan Schofield Hood Thabit Lalantha Leelarathna
author_facet	Kyuhan Lee Shakthi Gunasinghe Alyson Chapman Lynne A. Findlow Jody Hyland Sheetal Ohol Andrea Urwin Martin K. Rutter Jonathan Schofield Hood Thabit Lalantha Leelarathna
author_sort	Kyuhan Lee
title	Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_short	Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_full	Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_fullStr	Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_full_unstemmed	Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre
title_sort	real-world outcomes of glucose sensor use in type 1 diabetes—findings from a large uk centre
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/2ef86de035a34cff94019bb89f5ec5ae
work_keys_str_mv	AT kyuhanlee realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT shakthigunasinghe realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT alysonchapman realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT lynneafindlow realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT jodyhyland realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT sheetalohol realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT andreaurwin realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT martinkrutter realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT jonathanschofield realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT hoodthabit realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre AT lalanthaleelarathna realworldoutcomesofglucosesensoruseintype1diabetesfindingsfromalargeukcentre
_version_	1718412829458956288

Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes—Findings from a Large UK Centre

Ejemplares similares